Amedisys - AMED Stock Forecast, Price & News

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes. As of December 31, 2021, the company owned and operated 331 home health care centers, 175 hospice care centers, and 14 personal-care, and 8 high acuity care centers in 38 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

Analysts Set New Price Targets

A number of analysts have weighed in on AMED shares. Stephens lowered their price target on Amedisys from $155.00 to $125.00 and set an "equal weight" rating on the stock in a research report on Tuesday, June 21st. Stifel Nicolaus started coverage on Amedisys in a research report on Tuesday, June 28th. They issued a "hold" rating and a $128.00 price target on the stock. Bank of America cut Amedisys from a "neutral" rating to an "underperform" rating and lowered their price target for the company from $145.00 to $102.00 in a research report on Tuesday, June 21st. SVB Leerink lowered their price target on Amedisys from $117.00 to $107.00 and set a "market perform" rating on the stock in a research report on Tuesday, June 21st. Finally, Oppenheimer decreased their target price on Amedisys from $200.00 to $175.00 in a report on Friday, July 29th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $158.53.

Amedisys Trading Up 2.4 %

Shares of AMED opened at $122.33 on Thursday. The company has a quick ratio of 0.92, a current ratio of 0.92 and a debt-to-equity ratio of 0.43. Amedisys has a 12-month low of $101.61 and a 12-month high of $193.86. The firm has a market capitalization of $3.97 billion, a PE ratio of 28.52, a price-to-earnings-growth ratio of 2.32 and a beta of 0.95. The stock's fifty day simple moving average is $118.70 and its 200-day simple moving average is $134.39.

Amedisys (NASDAQ:AMED - Get Rating) last issued its quarterly earnings results on Wednesday, July 27th. The health services provider reported $1.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.24. Amedisys had a return on equity of 17.81% and a net margin of 6.33%. The business had revenue of $557.89 million for the quarter, compared to analyst estimates of $583.12 million. During the same quarter in the prior year, the firm posted $1.69 earnings per share. The firm's revenue for the quarter was down 1.1% compared to the same quarter last year. As a group, research analysts predict that Amedisys will post 5.34 earnings per share for the current year.

Insider Activity

In other Amedisys news, insider Denise M. Bohnert sold 557 shares of the stock in a transaction dated Thursday, June 23rd. The stock was sold at an average price of $115.00, for a total value of $64,055.00. Following the transaction, the insider now owns 11,850 shares of the company's stock, valued at $1,362,750. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 2.10% of the stock is currently owned by insiders.